Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
In a recent survey conducted, we found that 90% of pharma respondents said their organization works with more than one contract manufacturing organization (CMO). The factors that are most important to pharma companies when choosing a CMO are:
While some pharma companies have a preferred CMO, some do not. Many CMOs have found themselves looking to seize new opportunities to expand their footprint in the market with so much innovation, intense competition, and price and cost pressures. With our unique strengths and expertise, we can help CMOs succeed in this environment.
We provide a unique range of marketing solutions to put you in touch with the pharmaceutical industry. Whatever your objectives, we can help you to reach your target audience the way they want to be contacted.
We can help fuel your strategic planning and decision-making with best-in-class data and personalized consulting. Partner with thought leaders that understand the industry and can advise on the best solutions for you and your team.
Track all drugs in development from bench to market with the industry’s most established and reputable drug database. This includes drug development by therapeutic areas, mechanisms, origins, targets, and more.
Track your competitor’s clinical trial research and development activity with the world’s most comprehensive real-time source of pharmaceutical clinical trials intelligence, supported by experienced industry analysts.
Biomedtracker provides real-time analysis of major market-moving events in the pharma and biotech industries. With catalyst tracking and expert insights, Biomedtracker helps you stay on top of breaking events, the drugs pipeline, upcoming milestones, companies, and deals – and their impact on the markets you care about.
Duncan Specialises in
23+ years of experience
Ly Specialises in
22+ years of experience
Daniel Specialises in
13+ years of experience
Shardha Specialises in
A recent subscriber survey of over 100 senior decision makers from across the pharma industry told us what’s important to them and the challenges they face when working with contract research organizations (CROs).
A recent subscriber survey of senior decision makers from across the pharma industry told us what’s important to them and the challenges they face when working with contract development and manufacturing organizations (CDMOs).
Welcome to Pharmaprojects’ 2022 review of trends in pharmaceutical R&D. For 30 years now, I’ve been taking an annual look at the evolution of pharma R&D, and in this article I’ll examine the state of play at the start of 2022.
We’re excited to share our latest report on gene, cell, and rna therapies with The American Society of Gene and Cell Therapy (ASGCT). This Q3 2022 report calls out important updates and changes within the gene, cell, and rna therapy landscape.
More than 1 in 6 drugs in development today are based upon sophisticated gene, cell, or RNA modalities. They are increasingly becoming part of mainstream R&D.
We will call you back as soon as possible.
